4D Medical’s Imbio Secures Research Agreement With U.S. Dept of Veteran Affairs

This project will use Imbio’s Lung Texture Analysis (LTA) to assess the CT scans of a cohort of Veterans who underwent Lung Cancer Screening (LCS) between 2014 and 2017 to determine the prevalence of interstitial lung disease (ILD).

By Simon Glover:

Melbourne, Australia, 27 February 2024: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces the signing of a research agreement with the VA.

The U.S. Veteran population suffers from ILD at a rate of 10 times the civilian population, with a 260% growth in the incidence of this debilitating condition since 2010.

Distinct from the Company’s ongoing efforts to diagnose Veterans with deployment related respiratory disease, this project broadens and accelerates 4DMedical’s engagement with the U.S. Department of Veterans Affairs (VA).

Veterans Affairs research agreement

4DMedical’s wholly owned subsidiary, Imbio, has secured a research agreement with the VA Center for Innovations in Quality, Effectiveness and Safety (IQuESt). The research project will use Imbio’s Lung Texture Analysis (LTA) to retrospectively assess the CT scans of a cohort of Veterans that underwent Lung Cancer Screening (LCS) between 2014 and 2017 to determine the prevalence, diagnostic delay, and mortality associated with interstitial lung abnormalities (ILA) and interstitial lung disease (ILD).

The U.S. Veteran population suffers from ILD at a rate of 10 times the civilian population, with a 260% growth in the incidence of this debilitating condition since 2010. Approximately 1 million Veterans are eligible for lung cancer screening (LCS), and up to 25% of these patients are projected to have findings of ILA/ILD based on lung cancer screening demonstration project data.

While the prevalence of high-risk features for ILA progression are not well characterised, lung texture analysis is effective in the classification of normal versus abnormal tissue, and performs well in distinguishing typical pathologies present in lungs with fibrotic disease. Imbio’s LTA product will be utilised to retrospectively assess a random sample of 2,000 patients with ILA/ILD from the national cohort, in the project titled, “Novel Machine Learning Tools to Reduce Diagnostic Delays Among Veterans with Pulmonary Fibrosis”.

Principal investigator from the Michael E. DeBakey Department of Veterans Affairs Medical Center,

Houston, Texas, Prof. Kaul, MD, stated in the research outline: “Our central hypothesis is that [Imbio] LTA can identify Veterans with fibrosis early in their disease process and expedite access to subspecialty care…Partnering with the VA’s national LCS program thus has the potential to improve early pulmonary fibrosis diagnosis as there are 900,000 Veterans eligible for lung cancer screening”.

Scientific aims of the project

The project will describe the prevalence of ILA and ILD among a national cohort of Veterans undergoing lung cancer screening. Because lung cancer screening is often led by primary care, under-reporting of radiographic abnormalities on CT may contribute to delays in pulmonary subspecialty referral, and subsequent initiation of appropriate therapy.

The project will quantify the delay between acquisition of the lung cancer screening CT and diagnosis of pulmonary fibrosis. Additionally, the project will quantify the degree of radiographic progression (change in percentage of fibrosis) between lung cancer CTs with evidence of fibrosis, and a 5-year follow up CT.

Additional baseline demographic, comorbidity and 5-year outcome data will be extracted from the

electronic health record. This additional data is important, as quantifying disease progression and mortality associated with ILA/ILD detected during lung cancer screening will help inform future risk prediction models and care for Veterans with these incidental findings.

4DMedical MD/CEO and Founder Andreas Fouras said:

4DMedical’s transformational acquisition of Imbio is already yielding results with an additional pathway to supporting lung health in the Veteran community. This research agreement is a major milestone in adding value to lung cancer screening programs in the VA and elsewhere, as we progress our LTA product to FDA approval later this year. 4DMedical’s demonstrated work to date with Veterans has been focussed on exposures to airborne hazards during deployment and I look forward to sharing further progress on this over the coming weeks and months.

 

Corporate
Chief Financial Officer
Simon Glover
[email protected]

Administration
Company Secretary
Naomi Lawrie
[email protected]

Media Enquiries
The Capital Network (TCN)
Julia Maguire
[email protected]

 

About 4DMedical

4DMedical Limited (ASX:4DX) is a pioneering global medical technology company revolutionizing the assessment of lung function in patients with respiratory diseases.

Using its proprietary XV Technology®, 4DMedical empowers healthcare professionals to precisely analyze regional airflow in the lungs, facilitating early detection and heightened sensitivity in identifying respiratory deficiencies as patients breathe.

Key Offerings:

XV Lung Ventilation Analysis Software (XV LVAS®): FDA-cleared software dynamically quantifying ventilation across the lungs.

CT LVAS™: Computed Tomography-enabled software offering similar capabilities.

Reports generated via 4DMedical’s Software as a Service (SaaS) model, compatible with existing hospital imaging systems or the groundbreaking XV Scanner.

In December 2023, 4DMedical expanded its portfolio with the acquisition of Imbio, a leading provider of AI-driven medical imaging solutions for chronic lung and cardiothoracic conditions. Imbio’s innovative solutions, cleared by regulatory authorities, enhance patient discovery, diagnosis, and treatment, fostering physician efficiency and personalized patient care.

This strategic move underscores 4DMedical’s commitment to advancing respiratory healthcare through cutting-edge technology and comprehensive solutions.

Articles of Interest